Zacks small cap research.
On January 17 th, electroCore announced preliminary 4Q:22 revenues of $2.5 million, which is ahead of our $2.2 million expectation. For 2022, revenues were $8.5 million, a 57% increase over 2021 levels. Strength in government channels, which produced a 56% increase were surpassed in percentage terms by growth in commercial which saw a …06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …How many stars would you give Zacks Investment Research? Join the 86 people who've already contributed. Your experience matters.
MIRA Continues to Pursue New Pain Relief. 11/14/2023. By Brad Sorensen, CFA. NASDAQ:MIRA. READ THE FULL MIRA RESEARCH REPORT. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it...Mar 3, 2023 · By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based on
On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) …Zacks Premium Research for ZSCCX View All Zacks Mutual Fund Rank #1's View the Zacks Mutual Fund Rank Guide Annual Return * 1 = Top 20%, 5 = Bottom 20% …
Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.78 to $16.84 per …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Mar 23, 2023 · By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include Aug 10, 2022 · By M. Marin NASDAQ:NVX | OTC:NVNXF READ THE FULL NVX RESEARCH REPORT Company positioning to benefit from ramping growth in target verticals Novonix (NASDAQ:NVX) (OTC:NVNXF) has a positive sector tailwind, in our opinion, as it advances its strategy to develop a U.S.-based lithium-ion battery materials supply chain. The company is an integrated developer and supplier of high-performance materials, SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …
Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ...
LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.
Nov 15, 2023 · SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the ... What's a "thinking cap" -- and could it make me a genius? It's doubtful, but this technology could help you. Learn more about the thinking cap here. Advertisement You couldn't have graduated from elementary school without a teacher instruc...When you start getting deeper into the world of investing, you’ll begin learning an entirely new, finance-specific vocabulary. From assets and mutual funds to expense ratios and the New York Stock Exchange, there’s certainly a lot to absorb...Q4 2022 gross margin increased to 30.9% from 24.3% a year ago and 29.2% in Q3 2022. The increase was primarily from the elimination of $20 million of low-margin revenues from the closure of the Japanese fab which were replaced by higher-margin sales generated from outside customers. Gross margin dollars increased by $25 million, or 25%.The Zacks Small/Mid Cap Core Portfolio (SMIZ) ETF represents the combination of our Small and Mid Cap separately managed accounts (SMAs), drawing upon over a decade of comprehensive research and analysis. Utilizing the Zacks Proprietary Multi-factor Alpha Model, our portfolio management team identifies a selection of the …
Aug 24, 2023 · By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ... May 30, 2023 · Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ... Aug 17, 2023 · The following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ... The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ... May 22, 2023 · By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ... “Yes! Success!” “Yes! Success!” It wasn’t quite “Mr. Watson. Come Here. I need you.” but it could prove to be just as revolutionary: Researchers at the University of Washington have completed the first experiment demonstrating human brain-t...
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 15, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com …Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising Estimates as Q2 Comes in Way Above Expectations and Company Turns a Profit Compared to its peers in the fintech space who trade at an average of 14.9 times SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2022 Financial Results On December 28, 2022, CEL-SCI Corporation (NYSE:CVM) submitted its fiscal year 2022 Form 10-K with the SEC concurrent with a press release announcing fiscal year 2022 results. ... SUBSCRIBE TO ZACKS SMALL CAP …Jan 5, 2023 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in the When it comes to maintaining and enhancing the appearance of your vehicle, even the smallest details matter. One such detail that often goes overlooked is the wheel center caps. These small, circular covers not only add a touch of style to ...Zacks Rank N/A Third Quarter Update Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 15, 2021 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)
By David Bautz, PhD. NASDAQ:KMDA. READ THE FULL KMDA RESEARCH REPORT. Financial Update. On March 15, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2022 and provided a business update. Kamada reported revenues of $129.3 million, which met the …
ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other …
A cap is an award given to a soccer player who represents his country in international matches. Each time a player participates in an international match, he is “capped.” Many soccer players have been capped, and several have reached 100 or...Aug 30, 2023 · The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ... By Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …Gain Therapeutics, Inc. today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, …3 Top-Ranked Beaten-Down Tech Stocks to Buy... AWS 10/6: Jobs Numbers Double to 336K on... PFP 10/6: All Eyes on This Morning's Jobs... Top Stock Reports for Alphabet, Sanofi &... A complete...Zacks Rank N/A A Precision Undertaking Zacks Small-Cap Research J Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 13, 2022 ohn D. Vandermosten, CFA 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ...2 days ago · This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ... ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other serious illnesses.
Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believeJan 5, 2023 · By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Instagram:https://instagram. mitsubishi ufj financial group incapple callsbest paper trading platform for optionshow much tax do i charge as a contractor Zacks Rank N/A A Precision Undertaking Zacks Small-Cap Research J Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 13, 2022 ohn D. Vandermosten, CFA 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) stock to buy nowsports stock Nov 14, 2023 · 11/14/2023 By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it continues to test and research its potential... brilliant earth group Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …